# Lumiere Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lumiere-therapeutics

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.ltcure.com
- Total disclosed funding: $15M
- Latest round: Angel (Jun 13, 2022)
- Investors on record: 3

## About

Established in 2021 and based in Jiangsu, China, Weiguang Jiyin (Suzhou) Co., Ltd., trading as Lumiere Therapeutics, is a healthcare company that focuses on developing human genetic diagnostic and therapeutic technologies. The company's founder and chief scientist officer (CSO), Professor Yangzhou Song, was the dean of the Chinese Academy of Life Sciences. 
In September 2026, Lumiere Therapeutics raised over CNY 100 million in Pre-series A funding co-led by Essential Capital and Huafang Capital, with participation from Efung Capital, Journey Leading Invest Management, Guangzhou Disruptive Fund, Zijin Venture Capital and other investors.

The company's main business is human gene diagnosis and therapy technology development, medical research and experimental development, cell technology research and application, engineering and technology research and experimental development, experimental analysis instruments sales, instrumentation sales and chemical products sales.

The company generates revenue by developing human genetic diagnostic and therapeutic technologies.

The company will use the latest funding to to advance the clinical development of innovative epigenetic drugs aimed at achieving clinical cures for chronic diseases, develop the company's new pipeline and continuously build its technology platforms, injecting strong momentum into its deep engagement in the field of epigenetic drug R&D.

## Funding rounds

- Angel, Jun 13, 2022, $15M — Apricot Capital, FC Innovation Venture Fund, Guangzhou Shenghao Investment Co., Ltd

## Investors

- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Angel
- FC Innovation Venture Fund (https://capitalatlas.ai/funds/fc-innovation-venture-fund) — Angel
- Guangzhou Shenghao Investment Co., Ltd — Angel